MONKEYPOX

This study checked the safety of the MVA-BN (Jynneos) vaccine in 500 adults working on a monkeypox study in the Democratic Republic of the Congo. Participants got two vaccine doses and were watched for side effects for up to 28 days after the last dose. The goal was to see how ma…

This study tested a new RNA-based vaccine (BNT166a) to prevent mpox (monkeypox). About 96 healthy adults received different doses to check safety and how well the vaccine triggers an immune response. The trial is complete, and results will help decide if the vaccine should move t…

This study tested whether giving smaller doses of the MVA-BN monkeypox vaccine under the skin (instead of the standard full dose into the fat) still provides good protection. About 229 healthy adults aged 18–50 received either one-fifth or one-tenth of the standard dose under the…

This study tested whether the MVA-BN vaccine for mpox works as well in teenagers (ages 12-17) as it does in adults. About 450 healthy participants received two doses of the vaccine. Researchers measured immune responses and monitored for side effects to see if the vaccine is safe…

This study tested whether the drug tecovirimat is safe and effective for treating monkeypox (mpox) in adults and children. Participants received either tecovirimat or a placebo along with standard care for 14 days. The main goal was to see how quickly skin lesions healed. The tri…

This study looked at 320 people with mpox to see what eye problems the virus can cause. Researchers checked for signs like vision loss, eye pain, and damage to different parts of the eye. The goal was to understand how often these complications happen, not to test a treatment.